Clinical trial · Observational
TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation
A Multicentre Observational Study on Treatment Approaches and HER2 Positive Status Prevalence in Different Stages of Bladder Cancer and PD-L1-positive Status in Metastatic Bladder Cancer in Russian Federation
NCT07038928CI-TRIAL-00121233RIVERSrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 15, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260915-000001
Summary
Brief summary (as posted)
A multicentre observational study on treatment approaches and HER2 positive status prevalence in different stages of bladder cancer and PD-L1-positive status in metastatic bladder cancer in Russian Federation
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- Patients with NMIBC
- description
- Non-muscle-invasive bladder cancer
- label
- Patients with MIBC
- description
- Muscle-invasive bladder cancer
- label
- Patients with mBC
- description
- Metastatic bladder cancer
Primary outcomes (20)
- measure
- Proportion of patients receiving any intravesical treatment among patients with high-risk NMIBC
- timeFrame
- 24 months
- description
- Proportion of patients receiving any intravesical treatment among patients with high-risk Non-muscle invasive bladder cancer (ongoing and anamnestic);
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years; * Signed ICF, including consent for FFPE tumor tissue sample testing; * Confirmed diagnosis of urothelial bladder cancer at NMIBC, MIBC, or mBC stage at study entry; * For patients with NMIBC: 1. TURBT performed at least 1 month but not more than 12 months prior to study entry; 2. Presence of ≥1 high-risk feature: * T1 tumor * High grade/G3 tumor * CIS (carcinoma in situ) * Multiple and recurrent and large (with diameter of largest tumor ≥3 cm) tumors (all conditions must be met in this point); * For patients with MIBC: Сystectomy performed at least 2 months but not more than 12 months prior to study entry; * For patients with mBC: mBC diagnosed during 12 months prior to study entry; * Availability of medical history data; * Availability of FFPE tumour tissue sample obtained during biopsy and/or surgery. Exclusion Criteria: • Participation in any interventional trial since the urothelial bladder cancer diagnosis.
References
Publications (0)
Data not yet available
No reference posted for this study.